The importance of sex-specific strategies for prevention, treatment of heart failure in women

February 25, 2019

WASHINGTON (Feb. 25, 2019) -- There are many important differences between women and men with heart failure, highlighting the importance of sex-specific strategies for prevention and treatment, according to three papers publishing today in JACC: Heart Failure. This special focus issue will explore heart failure in women.

"Primary Prevention of Heart Failure in Women"

Men and women exhibit different heart failure risk factors and mechanisms, demonstrating the importance of sex-specific prevention strategies for heart failure. Unfortunately, women are frequently underrepresented in clinical trials for heart failure and data on the effectiveness of heart failure interventions in women are lacking. A review paper examines the different efforts that should be taken to prevent heart failure in women.

Women with heart failure are generally older, have a higher BMI and have a greater prevalence of hypertension, diabetes and kidney disease. Women are more likely to have heart failure with preserved ejection fraction (HFpEF), while men are more likely to have heart failure with reduced ejection fraction (HFrEF). Atrial fibrillation (AFib) has also been shown to have a sex-specific predictive value for the development of HFpEF in women. Interventions targeted at maintaining or achieving a health body weight and reducing risk factors, especially hypertension and AFib, may help to lower the rates of heart failure in women. Additionally, pregnancy complications, breast cancer treatments and menopause can all increase the risk of heart failure in women.

"Women need to be adequately represented in clinical research and sex differences prospectively investigated," said Melissa A. Daubert, MD, cardiologist at Duke University and lead author of the paper. "In the meantime, incorporating specific recommendations for women into clinical guidelines when data are sufficient will likely improve heart failure outcomes and decrease health disparities in women."

"Is Cardiac Diastolic Dysfunction a Part of Post-Menopausal Syndrome?"

Postmenopausal women display an exponential increase in the incidence of HFpEF compared to men of the same age, indicating that hormonal changes may affect heart function. A review paper in this issue examines the involvement of estrogen on cardiac function in postmenopausal women.

"Estrogen deficiency influences both early diastolic relaxation via calcium regulation and late diastolic compliance associated with a thickening of the heart muscles," said Jagat Narula, MD, PhD, professor of medicine at Mount Sinai Hospital and senior author of the paper.

Changes in heart function and structure are often seen in older age in both men and women. These changes are more pronounced in postmenopausal women compared to premenopausal women, indicating that estrogen deficiency may be to blame.

"In women at a lower risk for heart failure, estrogen deficiency combined with other risk factors such as hypertension, diabetes or obesity might lead to the development of full-blown clinical syndrome," Narula said.

Studies have inconclusively found that hormone replacement therapy could improve heart function in postmenopausal women, but more clinical trials and data are still needed.

"Long-term Risk of Heart Failure in Breast Cancer Patients After Adjuvant Chemotherapy With or Without Trastuzumab"

Trastuzumab treatment has been shown to significantly improve the outcomes of patients with a certain kind of breast cancer, but it is also associated with a two-fold increased risk of heart failure compared to other chemotherapy regimens, according to a study in this issue of JACC: Heart Failure.

Human Epidermal Growth Factor Receptor 2 (HER2) breast cancer is associated with a poor prognosis. While trastuzumab has significantly improved survival in these patients, previous studies have shown an increased risk in heart failure within the first two years after treatment. Long-term risks remain more uncertain.

This study included 8,812 patients scheduled for adjuvant therapy for early-stage breast cancer. A total of 2,117 had HER2 positive breast cancer and received both chemotherapy and trastuzumab, while 6,695 HER2 negative patients received chemotherapy only. The final cohort consisted of 8,611 patients who survived and did not develop heart failure within the first 18 months after treatment.

After a median follow-up period of 5.4 years, 2.7 percent of patients who received trastuzumab developed new cases of heart failure compared to 0.8 percent who received chemotherapy only. The cumulative incidence of heart failure after nine years was 3.3 percent in the trastuzumab group compared to 1.3 percent in the chemotherapy only group. These results demonstrate a significant increase in both early and late heart failure among patients treated with both chemotherapy and trastuzumab compared to chemotherapy alone but with an overall low incidence.

"With many long-term survivors after modern breast cancer treatment, awareness of heart failure as a possible long-term consequence of trastuzumab treatment is important," said Ann Banke, MD, a researcher at Odense University Hospital in Denmark and the lead author of the study. "Even though overall risk of heart failure after trastuzumab treatment is low, it might be relevant to take this risk into consideration when planning the course of follow-up after HER2 positive breast cancer, especially in patients with other comorbidities, as this seems associated with a later diagnosis of heart failure."

In an editor's page publishing in the issue, JoAnn Lindenfeld, MD, and JACC: Heart Failure Editor-in-Chief Christopher O'Connor, MD, write that this issue demonstrates that, "there are important differences in clinical characteristics, comorbidities and overall characteristics of women with heart failure compared to men with heart failure. In addition, we described important differences in hospitalization rates, use of advanced heart failure therapies and mortality."

They add that the goals of this important issue of the journal are to increase awareness in these differences between heart failure in men and women, to encourage research that looks at the outcomes by sex, and to provide patients with the information and knowledge needed to make informed decisions and be ensured they are receiving the best care.
-end-
The American College of Cardiology envisions a world where innovation and knowledge optimize cardiovascular care and outcomes. As the professional home for the entire cardiovascular care team, the mission of the College and its more than 52,000 members is to transform cardiovascular care and to improve heart health. The ACC bestows credentials upon cardiovascular professionals who meet stringent qualifications and leads in the formation of health policy, standards and guidelines. The College also provides professional medical education, disseminates cardiovascular research through its world-renowned JACC Journals, operates national registries to measure and improve care, and offers cardiovascular accreditation to hospitals and institutions. For more, visit acc.org.

The Journal of the American College of Cardiology ranks among the top cardiovascular journals in the world for its scientific impact. JACC is the flagship for a family of journals--JACC: Cardiovascular Interventions, JACC: Cardiovascular Imaging, JACC: Heart Failure, JACC: Clinical Electrophysiology and JACC: Basic to Translational Science--that prides themselves in publishing the top peer-reviewed research on all aspects of cardiovascular disease. Learn more at JACC.org.

American College of Cardiology

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.